INCYTE CORPORATION Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)
INCYTE CORPORATION (INCY) reported Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) of -$27.68 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-10.
Financial Statements › Notes › Compensation Related Costs › Defined Benefit Plan › Defined Benefit Plan, Roll Forwards
us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation · last filed 2026-02-10
- INCYTE CORPORATION defined benefit plan, benefit obligation, foreign currency translation gain (loss) for fiscal 2025 was -$27.68M, a 328.72% decline from fiscal 2024.
- INCYTE CORPORATION defined benefit plan, benefit obligation, foreign currency translation gain (loss) for fiscal 2024 was $12.10M.
- INCYTE CORPORATION defined benefit plan, benefit obligation, foreign currency translation gain (loss) for fiscal 2023 was -$13.01M, a 1002.64% decline from fiscal 2022.
- INCYTE CORPORATION defined benefit plan, benefit obligation, foreign currency translation gain (loss) for fiscal 2022 was $1.44M, a 48.30% decline from fiscal 2021.
| Period end | Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) 12 month | Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$27.68M 10-K · filed 2026-02-10 | |
| 2024-12-31 | $12.10M 10-K · filed 2026-02-10 | |
| 2023-12-31 | -$13.01M 10-K · filed 2025-02-10 | |
| 2022-12-31 | $1.44M 10-K · filed 2024-02-13 | |
| 2021-12-31 | $2.79M 10-K · filed 2023-02-07 | |
| 2020-12-31 | -$6.37M 10-K · filed 2022-02-08 | |
| 2019-12-31 | -$784.00K 10-K · filed 2021-02-09 | |
| 2018-12-31 | $471.00K 10-K · filed 2020-02-13 | |
| 2017-12-31 | -$909.00K 10-K · filed 2019-02-14 | $909.00K 10-K · filed 2018-02-15 |
| 2016-12-31 | -$418.00K 10-K · filed 2018-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| IQVIA HOLDINGS INC. (IQV) | United States | $45.926B | 20.54 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B |